Acquisition Of MSC Lung Cancer Screening Test Sends Shares Of This Micro Cap Higher

Sponsored:

Tuesday, March 18, 2025

Lung cancer is the leading cause of cancer-related deaths worldwide, accounting for more deaths than breast, colon, and prostate cancers combined. With those sobering stats, any medical advancement / enhancement would be great news for all.

A U.S. listed microcap is adding one new tool to the tool kit in the fight to try and improve outcomes for patients with or at risk of cancer. AccuStem Sciences, Inc. (OTCQB: ACUT) announced this morning the acquisition of the license for the proprietary microRNA Signature Classifier (MSC) test. 

The MSC test was developed by researchers Mattia Boeri, PhD, Ugo Pastorino, MD, and Gabriella Sozzi, PhD, at the Istituto Nazionale Tumori (INT) to help physicians more accurately screen patients at risk of lung cancer. The blood-based test evaluates 24 micro RNAs to improve the diagnostic performance of low-dose computed tomography (LDCT) in patients with pulmonary nodules.

By utilizing MSC in combination with LDCT, clinicians will be able to more accurately stratify and manage lung nodules. Data published in Annals of Oncology show that MSC+/LDCT+ patients have a cumulative lung cancer incidence 30-fold higher than MSC-/LDCT- patients whose screening intervals could be safely delayed without reducing the detection of early-stage, curable cancers. 

Further, analyses published in the Journal of Clinical Oncology show that combining MSC with LDCT results in a five-fold reduction in false positives compared to LDCT alone, which could lead to improved patient outcomes, fewer biopsies and lower healthcare costs.

The consideration for the acquisition is to be satisfied by the issue of 3,750,000 common shares in the capital of AccuStem.

Despite broader weakness on the markets, shares of ACUT are currently eking out a small gain on the day with shares currently up 0.48% at $0.3626 in mid-morning trading.

Sponsored: